

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6027566

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	IGM BIOSCIENCES, INC.	12/29/2017
RECEIVING PARTY DATA		
Name:	IGM BIOSCIENCES A/S	
Street Address:	HALDOR TOPSØES ALLÉ 1	
City:	LYNGBY	
State/Country:	DENMARK	
Postal Code:	2800 KGS.	
PROPERTY NUMBERS Total: 2		
Property Type	Number	
Application Number:	16136049	
Application Number:	16803745	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2022869629	
Email:	patents@IGMbio.com	
Correspondent Name:	ELIZABETH J. HAANES	
Address Line 1:	IGM BIOSCIENCES, INC.	
Address Line 2:	325 EAST MIDDLEFIELD ROAD	
Address Line 4:	MOUNTAIN VIEW, CALIFORNIA 94043	
ATTORNEY DOCKET NUMBER:	004-015US3&004-015US4	
NAME OF SUBMITTER:	ELIZABETH J. HAANES	
SIGNATURE:	/Elizabeth J. Haanes, Reg. No.: 42,613/	
DATE SIGNED:	03/23/2020	
Total Attachments: 14		
source=2-015US3-Executed-Assignment-Inc-to-AS#page1.tif		
source=2-015US3-Executed-Assignment-Inc-to-AS#page2.tif		
source=2-015US3-Executed-Assignment-Inc-to-AS#page3.tif		
source=2-015US3-Executed-Assignment-Inc-to-AS#page4.tif		

source=2-015US3-Executed-Assignment-Inc-to-AS#page5.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page6.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page7.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page8.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page9.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page10.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page11.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page12.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page13.tif
source=2-015US3-Executed-Assignment-Inc-to-AS#page14.tif

ASSIGNMENT OF PATENT RIGHTS

This Assignment is effective October 29, 2007 between IGM Biosciences, Inc and IGM Biosciences A/S.

WHEREAS IGM Biosciences, Inc., a corporation of Delaware, having its principal office and place of business at 325 E. Middlefield Rd, Mountain View, CA 94043, USA ("ASSIGNOR"), owns rights in the patents and patent applications set forth in **Schedule A** (the "Patent Rights"); and

WHEREAS IGM Biosciences A/S (company registration number (CVR no.) 39 12 36 49), a corporation of Denmark, having its principal office and place of business at Haldor Topsøes Allé 1, 2800 Kgs. Lyngby, Denmark ("ASSIGNEE"), is desirous of acquiring ASSIGNOR's entire right, title, and interest in and to said Patent Rights.

THEREFORE, in consideration of the sum of one United States dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby assigns to ASSIGNEE its entire right, title and interest in and to said Patent Rights and improvements as the same are disclosed in said Patent Rights, in and to any and all letters patent(s) and applications filed therefor, including provisionals, non-provisionals, divisionals, continuations, reissues, reexaminations, and extensions to be obtained therefor in the United States and all foreign countries, including all priority rights and all rights to claim priority; and ASSIGNOR further agrees to cooperate with ASSIGNEE hereunder in the obtaining and sustaining of any and all such Letters Patent(s) as ASSIGNEE may desire to apply for.

The Commissioner of Patents or other proper official is hereby authorized and requested to issue said Patent Rights to ASSIGNEE in accordance with this Assignment.

ASSIGNOR hereby authorizes and requests the attorneys of record in said Patent Rights to insert in this Assignment the serial number, filing date, and date of execution of any items of said Patent Rights for the purposes of recording this Assignment.

For said consideration, ASSIGNOR hereby agrees, upon the request of ASSIGNEE, to execute any provisional, non-provisional, divisional, continuation, continuation-in-part, or substitute application for said Patent Rights, and any oath or affidavit relating thereto, and any application for the reissue or extension of any letters patent that may be granted upon said Patent Rights, and, in the event of any application or letters patent of the Patent Rights becoming involved in an interference, opposition, post-grant review, inter-partes review, litigation, or any other proceeding in the United States or any foreign country, to cooperate to the best of its ability in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof. ASSIGNOR agrees to perform, upon request, any affirmative acts to obtain letters patents from the Patent Rights and vest in ASSIGNEE all rights therein, whereby said Patent Rights will be held and enjoyed by ASSIGNEE, to the full end of the term for which said Patent Rights may be granted as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this Assignment had not been made.

And for said consideration, ASSIGNOR hereby assigns to ASSIGNEE its entire right, title and interest in said Patent Rights for all foreign countries, including all priority rights, and agrees to execute, at the request of ASSIGNEE, all documents in connection with any application for foreign letters patent within the Patent Rights.

This Assignment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Assignment by facsimile or in electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this Assignment.

IN WITNESS WHEREOF, I have hereunto set my hand the 29th day of December, 2017.

ASSIGNOR:

IGM Biosciences, Inc.

By: 

Name: Fred M. Schwarzer

Title: CEO

Only if required by local law:


STATE OF CALIFORNIA)


County of Santa Clara) §

On December 29, 2017, before me, Sandra L Foster a Notary Public, personally appeared Fred Schwarzer who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct

WITNESS my hand and official seal.


Signature of Notary




(Affix seal here)


SCHEDULE 4

IN WITNESS WHEREOF, I have hereunto set my hand the 8th day of January 2018.

ASSIGNEE:

IGM Biosciences A/S

By: 
Name: Hans Kornerup
Title: CEO

By: 
Name: Jakob Haldor Topsøe
Title: Chairman of the Board of Directors

SCHEDULE A
Patents

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-04-15	2016249404		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-04-15	2983034		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	China	Application	2016-04-15	Natl. phase of PCT/US2016/0 27979 (to be assigned)		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-04-15	16780944.1		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-04-15	2017-554329		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-04-15	PCT/US2016/0 27979		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-04-17	62/149460		
MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-04-15	15/566,485		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-03-25	2016238246		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-03-25	2980751		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	China	Application	2016-03-25	Natl. Phase of PCT/US2016/024348 (to be assigned)		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-03-25	16769812.5		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-03-25	2017-549723		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-03-25	10-2017-7030451		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-03-25	PCT/US2016/024348		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-03-25	62/137881		
MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-03-25	15/560905		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-01-20	2016209324		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-01-20	2,972,990		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	China	Application	2016-01-20	201680006321.X		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-01-20	16740686.7		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	India	Application	2016-01-20	201737020527		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Israel	Application	2016-01-20	253054		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-01-20	2017-556795.		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-01-20	10-2017-702273		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	New Zealand	Application	2016-01-20	732922		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-01-20	PCT/US2016/014153		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	Singapore	Application	2016-01-20	11201705116S		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-01-20	62/105323		
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-01-20	15/544,873		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF	United States of America	Application	2017-06-30	15/638748		
CD20 BINDING MOLECULES AND USES THEREOF	Australia	Application	2016-03-04	2016226060		
CD20 BINDING MOLECULES AND USES THEREOF	Brazil	Application	2016-03-04	BR112017018941-0		
CD20 BINDING MOLECULES AND USES THEREOF	Canada	Application	2016-03-04	2,978,324		
CD20 BINDING MOLECULES AND USES THEREOF	China	Application	2016-03-04	201680026078.8		
CD20 BINDING MOLECULES AND USES THEREOF	European Patent	Application	2016-03-04	16759586.7		
CD20 BINDING MOLECULES AND USES THEREOF	India	Application	2016-03-04	201717033549		
CD20 BINDING MOLECULES AND USES THEREOF	Israel	Application	2016-03-04	254223		
CD20 BINDING MOLECULES AND USES THEREOF	Japan	Application	2016-03-04	2017-546081		
CD20 BINDING MOLECULES AND USES THEREOF	Korea, Republic of (KR)	Application	2016-03-04	10-2017-7027838		
CD20 BINDING MOLECULES AND USES THEREOF	New Zealand	Application	2016-03-04	735607		
CD20 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Closed	2016-03-04	PCT/US2016/020920		
CD20 BINDING MOLECULES AND USES THEREOF	Singapore	Application	2016-03-04	11201707144V		
CD20 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2015-03-04	62/128284		
CD20 BINDING MOLECULES AND USES THEREOF	United States of America	Application	2016-03-04	15/554,301		
MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-20	PCT/US2017/043165		
MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364763		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
MULTIMERIC G1TR BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-20	PCT/US2017/043166		
MULTIMERIC G1TR BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364762		
MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-19	PCT/US2017/042931		
MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364760		
MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF	Patent Cooperation Treaty	Application	2017-07-19	PCT/US2017/042933		
MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF	United States of America	Expired	2016-07-20	62/364758		
MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION	United States of America	Application	2017-04-07	62/483087		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Australia	Application	2014-09-04	2014332458		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Brazil	Application	2014-09-04	BR112016004768-0		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Canada	Application	2014-09-04	2,922,830		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	China	Application	2014-09-04	201480051238.5		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	European Patent	Application	2014-09-04	14766628.3		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	India	Application	2014-09-04	201647010705		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Japan	Application	2014-09-04	2016-540383		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Korea, Republic of (KR)	Application	2014-09-04	10-2016-7007082		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	Patent Cooperation Treaty	Closed	2014-09-04	PCT/US2014/054079		
CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES	United States of America	Application	2014-09-04	14/916,166		
BINDING MOLECULES	United States of America	Expired	2013-09-05	61/874,277		
BINDING MOLECULES	United States of America	Expired	2013-09-05	61/874,284		
IGA MULTI-SPECIFIC BINDING MOLECULES	Australia	Application	2015-02-10	2015213593		
IGA MULTI-SPECIFIC BINDING MOLECULES	Brazil	Application	2015-02-10	BR112016018313-4		
IGA MULTI-SPECIFIC BINDING MOLECULES	Canada	Application	2015-02-10	2,939,191		
IGA MULTI-SPECIFIC BINDING MOLECULES	China	Application	2015-02-10	201580007952.9		
IGA MULTI-SPECIFIC BINDING MOLECULES	European Patent	Application	2015-02-10	15706611.9		
MULTI SPECIFIC IGA BINDING MOLECULES	Hong Kong	Application	2016-08-11	17104620.1		
IGA MULTI-SPECIFIC BINDING MOLECULES	India	Application	2015-02-10	201647030490		
IGA MULTI-SPECIFIC BINDING MOLECULES	Japan	Application	2015-02-10	2016-568481		
IGA MULTI-SPECIFIC BINDING MOLECULES	Korea, Republic of (KR)	Application	2015-02-10	10-2016-7024677		
IGA MULTI-SPECIFIC BINDING MOLECULES	Patent Cooperation Treaty	Closed	2015-02-10	PCT/US2015/015268		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
IGA MULTI-SPECIFIC BINDING MOLECULES	United States of America	Application	2015-02-10	15/117,432		
MULTI SPECIFIC IGA BINDING MOLECULES	United States of America	Expired	2014-02-10	61/937,984		
MODIFIED J-CHAIN	Australia	Application	2015-04-02	2015240595		
MODIFIED J-CHAIN	Brazil	Application	2015-04-02	BR112016022841-3		
MODIFIED J-CHAIN	Canada	Application	2015-04-02	2,944,647		
MODIFIED J-CHAIN	China	Application	2015-04-02	201580018643.1		
MODIFIED J-CHAIN	European Patent	Application	2015-04-02	15718304.7		
MODIFIED J-CHAIN	India	Application	2015-04-02	201647037003		
MODIFIED J-CHAIN	Israel	Application	2015-04-02	248151		
MODIFIED J-CHAIN	Japan	Application	2015-04-02	2016-560487		
MODIFIED J-CHAIN	Korea, Republic of (KR)	Application	2015-04-02	10-2016-7030462		
MODIFIED J-CHAIN	Mexico	Application	2015-04-02	MX/a/2016/012880		
MODIFIED J-CHAIN	New Zealand	Application	2015-04-02	725568		
MODIFIED J-CHAIN	Patent Cooperation Treaty	Closed	2015-04-02	PCT/US2015/024149		
MODIFIED J-CHAIN	Russian Federation	Application	2015-04-02	2016141579		
MODIFIED J-CHAIN	Singapore	Application	2015-04-02	11201608194V		
MODIFIED J-CHAIN	South Africa	Application	2015-04-02	2016/06906		
MODIFIED J CHAIN	United States of America	Application	2017-03-07	15/452616		
MODIFIED J-CHAIN	United States of America	Application	2015-04-02	15/301,366		
MODIFIED J CHAIN	United States of America	Expired	2014-04-03	61/974,738		
BINDING MOLECULES WITH MODIFIED J-CHAIN	Patent Cooperation Treaty	Published	2016-09-30	PCT/US2016/055053		

Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Expired	2015-09-30	62/235,486		
BINDING MOLECULES WITH MODIFIED J-CHAIN	Patent Cooperation Treaty	Published	2016-09-30	PCT/US2016/055041		
BINDING MOLECULES WITH MODIFIED J-CHAIN	United States of America	Expired	2015-09-30	62/235,518		
ANTI-PD-L1 ANTIBODIES	Patent Cooperation Treaty	Application	2017-05-09	PCT/US2017/031791		
ANTI-PD-L1 ANTIBODIES	United States of America	Expired	2016-05-09	62/333,643		
ANTIBODY MOLECULE VARIANTS	United States of America	Application	2017-03-30	62/479161		
Antibody Induced Cell Membrane Wounding	Austria	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Denmark	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	European Patent	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Finland	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Germany (Federal Republic of)	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Italy	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Netherlands	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	Patent Cooperation Treaty	Expired	2005-11-04	PCT/US2005/039762		
Antibody Induced Cell Membrane Wounding	Sweden	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	United Kingdom	Granted	2005-11-04	05818169.4	2015-08-19	1814913
Antibody Induced Cell Membrane Wounding	United States of America	Granted	2005-11-04	11/267,935	2013-02-19	8377435
Antibody Induced Cell Membrane Wounding	United States of America	Granted	2013-02-19	13/770,619	2016-10-04	9458241
Antibody Induced Cell Membrane Wounding	United States of America	Expired	2004-11-05	60/625,398		
CDIM Binding Proteins and Uses Thereof	Australia	Granted	2013-02-08	2013200903	2015-08-27	2013200903


Title	Country	Status	Filed Date	App. No.	Grant Date	Patent No.
CDIM Binding Proteins and Uses Thereof	Brazil	Published	2013-02-08	BR11201401945.9		
CDIM Binding Proteins and Uses Thereof	Canada	Application	2013-02-08	2863714		
CDIM Binding Proteins and Uses Thereof	China	Granted	2013-02-08	201380008515.X	2017-04-26	ZL201380008515.X
CDIM Binding Proteins and Uses Thereof	European Patent	Published	2013-02-08	13713588.5		
CDIM Binding Proteins and Uses Thereof	Hong Kong	Application	2013-02-08	15105490.7		
CDIM Binding Proteins and Uses Thereof	India	Application	2013-02-08	1781/MUMNP/2014		
CDIM Binding Proteins and Uses Thereof	Japan	Application	2013-02-08	2014-556751		
CDIM Binding Proteins and Uses Thereof	Korea, Republic of (KR)	Application	2013-02-08	10-2014-7025110		
CDIM Binding Proteins and Uses Thereof	Mexico	Application	2013-02-08	MX/a/2014/009628		
CDIM Binding Proteins and Uses Thereof	Patent Cooperation Treaty	Expired	2013-02-08	PCT/US2013/025430		
CDIM Binding Proteins and Uses Thereof	Taiwan	Granted	2013-02-08	102105337		
CDIM Binding Proteins and Uses Thereof	United States of America	Granted	2013-02-08	13/763,398	2016-08-09	9409976
CDIM Binding Proteins and Uses Thereof	United States of America	Expired	2012-02-08	61/633,330		



This is to certify that **Mr. Hans Kornerup and Mr. Jakob Haldor Topsøe**, who today in my presence at the Notarial Office approved and signed this document, pursuant to a transcript from The Danish Business Authority, dated 05.01.2018, have powers to sign on behalf of the Company **IGM BIOSCIENCES A/S Cvr.no. 39123649**.

Mr. Hans Kornerup and Mr. Jakob Haldor Topsøe have proved their identities by presenting Driving Licences.

The District Court of Lyngby, Denmark the 8th day of January 2018.


Karina Myjak
Notary Public

